Trials / Completed
CompletedNCT03310645
Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients
Two-part, Double-blind, Placebo-controlled, Randomized, Parallel-group Study: (Part 1) in Healthy Male Volunteers to Assess Safety and Tolerability of Ascending Repeated Oral Doses of BAY1817080, Followed by (Part 2), Two-way Crossover Administration of Four Different Doses in Patients With Refractory Chronic Cough to Assess Safety, Tolerability and Efficacy for Proof of Concept
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 87 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the safety and tolerability of ascending repeated oral doses of BAY1817080 in healthy volunteers(Part1). To investigate the safety, tolerability and efficacy of BAY1817080 in patients with refractory chronic cough(Part2).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BAY1817080 | 4 different doses over the course of study |
| DRUG | Matching Placebo | Matching placebo for BAY1817080 |
Timeline
- Start date
- 2017-12-07
- Primary completion
- 2019-05-28
- Completion
- 2019-06-19
- First posted
- 2017-10-16
- Last updated
- 2023-01-26
Locations
7 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03310645. Inclusion in this directory is not an endorsement.